Jorge Alsina‐Fernandez

2.5k total citations · 1 hit paper
20 papers, 1.2k citations indexed

About

Jorge Alsina‐Fernandez is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Jorge Alsina‐Fernandez has authored 20 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Jorge Alsina‐Fernandez's work include Diabetes Treatment and Management (8 papers), Regulation of Appetite and Obesity (5 papers) and Pancreatic function and diabetes (5 papers). Jorge Alsina‐Fernandez is often cited by papers focused on Diabetes Treatment and Management (8 papers), Regulation of Appetite and Obesity (5 papers) and Pancreatic function and diabetes (5 papers). Jorge Alsina‐Fernandez collaborates with scholars based in United States, Sweden and Australia. Jorge Alsina‐Fernandez's co-authors include Tamer Coşkun, Kyle W. Sloop, Krister Bokvist, Daniel A. Briere, Axel Haupt, Shweta Urva, David A. D’Alessio, Charles Benson, Julie S. Moyers and Over Cabrera and has published in prestigious journals such as Cell, PLoS ONE and Diabetes.

In The Last Decade

Jorge Alsina‐Fernandez

19 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

2018 603 citations Tamer Coşkun, Kyle W. Sloop et al. Molecular Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jorge Alsina‐Fernandez United States	13	699	467	386	272	264	20	1.2k
Carrie Wittmer United States	12	397 0.6×	199 0.4×	306 0.8×	192 0.7×	78 0.3×	12	951
M. Bensaïd France	7	213 0.3×	206 0.4×	271 0.7×	132 0.5×	417 1.6×	18	871
Andrea Navarria Italy	12	728 1.0×	607 1.3×	139 0.4×	181 0.7×	436 1.7×	21	1.4k
Loren Lindsley United States	5	178 0.3×	550 1.2×	998 2.6×	128 0.5×	189 0.7×	5	1.5k
Lærke Egefjord Denmark	10	370 0.5×	191 0.4×	331 0.9×	166 0.6×	75 0.3×	10	834
Valerie Piercy United Kingdom	10	155 0.2×	464 1.0×	711 1.8×	246 0.9×	237 0.9×	15	1.3k
Nina Perwitz Germany	14	149 0.2×	198 0.4×	402 1.0×	112 0.4×	129 0.5×	17	704
R.M. Amy Canada	20	241 0.3×	285 0.6×	324 0.8×	177 0.7×	108 0.4×	24	869
Anish Konkar United States	14	132 0.2×	429 0.9×	530 1.4×	113 0.4×	67 0.3×	28	1.1k
Kazuhiro Momose Japan	13	193 0.3×	447 1.0×	139 0.4×	165 0.6×	74 0.3×	26	877

Countries citing papers authored by Jorge Alsina‐Fernandez

Since Specialization

Citations

This map shows the geographic impact of Jorge Alsina‐Fernandez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Alsina‐Fernandez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Alsina‐Fernandez more than expected).

Fields of papers citing papers by Jorge Alsina‐Fernandez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Alsina‐Fernandez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Alsina‐Fernandez. The network helps show where Jorge Alsina‐Fernandez may publish in the future.

Co-authorship network of co-authors of Jorge Alsina‐Fernandez

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Alsina‐Fernandez. A scholar is included among the top collaborators of Jorge Alsina‐Fernandez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Alsina‐Fernandez. Jorge Alsina‐Fernandez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Briere, Daniel A., Hongchang Qu, Katherine Lansu, et al.. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 102. 102271–102271. 4 indexed citations

Roell, William C., Tamer Coşkun, Teayoun Kim, et al.. (2024). Characterization of LY3324954 a long-acting glucagon-receptor agonist. Molecular Metabolism. 91. 102073–102073. 2 indexed citations

Urva, Shweta, Libbey S. O′Farrell, Yu Du, et al.. (2023). The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obesity and Metabolism. 25(9). 2784–2788. 19 indexed citations

Heuer, Josef G., Catalina M. Meyer, Hana E. Baker, et al.. (2022). Pharmacological Evaluation of a Pegylated Urocortin-1 Peptide in Experimental Autoimmune Disease Models. Journal of Pharmacology and Experimental Therapeutics. 382(3). 287–298.

Samms, Ricardo J., Richard Cosgrove, Brian A. Droz, et al.. (2022). GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior. Diabetes. 71(7). 1410–1423. 46 indexed citations

Coghlan, Matthew P., Libbey S. O′Farrell, Aaron D. Showalter, et al.. (2021). 639-P: GIP Receptor Agonism Enhances Weight Loss from Either a Biased or an Unbiased GLP-1 Receptor Agonist in DIO Mice. Diabetes. 70(Supplement_1). 2 indexed citations

Borg, Melissa L., Julie Massart, Thaís de Castro Barbosa, et al.. (2021). Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity‐induced insulin resistance. Journal of Cachexia Sarcopenia and Muscle. 12(5). 1232–1248. 16 indexed citations

Borner, Tito, Caroline E. Geisler, Samantha M. Fortin, et al.. (2021). GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models. Diabetes. 70(11). 2545–2553. 125 indexed citations

Coşkun, Tamer, Julie S. Moyers, William C. Roell, et al.. (2021). 679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes. Diabetes. 70(Supplement_1). 9 indexed citations

10.

Yu, Xiaopeng, Jill A. Willency, Keyun Qing, et al.. (2019). Long-Acting and Selective Oxytocin Peptide Analogs Show Antidiabetic and Antiobesity Effects in Male Mice. Journal of the Endocrine Society. 3(7). 1423–1444. 29 indexed citations

11.

Borg, Melissa L., Julie Massart, Milena Schönke, et al.. (2019). Modified UCN2 Peptide Acts as an Insulin Sensitizer in Skeletal Muscle of Obese Mice. Diabetes. 68(7). 1403–1414. 15 indexed citations

12.

Coşkun, Tamer, Kyle W. Sloop, Corina Loghin, et al.. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 18. 3–14. 603 indexed citations breakdown →

13.

Li, Yongguo, Monja Willershäuser, Josefine Reber, et al.. (2018). Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation. Cell. 175(6). 1561–1574.e12. 167 indexed citations

14.

Qian, Yuewei, J. Jack Lee, Jorge Alsina‐Fernandez, et al.. (2018). Deciphering Binding Interactions of IL-23R with HDX-MS: Mapping Protein and Macrocyclic Dodecapeptide Ligands. ACS Medicinal Chemistry Letters. 9(9). 912–916. 11 indexed citations

15.

Peterson, Richard G., et al.. (2017). Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse. PLoS ONE. 12(6). e0179856–e0179856. 27 indexed citations

16.

Bokvist, Krister, et al.. (2016). Thioredoxin-mimetic peptides (TXM) inhibit inflammatory pathways associated with high-glucose and oxidative stress. Free Radical Biology and Medicine. 99. 557–571. 24 indexed citations

17.

Willard, Francis S., Denise Wootten, Aaron D. Showalter, et al.. (2012). Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin. Molecular Pharmacology. 82(6). 1066–1073. 44 indexed citations

18.

Stengel, Andreas, Tamer Coşkun, Miriam Goebel‐Stengel, et al.. (2011). Chronic injection of pansomatostatin agonist ODT8-SST differentially modulates food intake and decreases body weight gain in lean and diet-induced obese rats. Regulatory Peptides. 167(2-3). 201–208. 4 indexed citations

19.

Goebel, Miriam, Andreas Stengel, Lixin Wang, et al.. (2010). Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in rats. Brain Research. 1351. 150–164. 12 indexed citations

20.

Stengel, Andreas, Tamer Coşkun, Miriam Goebel, et al.. (2010). Central Injection of the Stable Somatostatin Analog ODT8-SST Induces a Somatostatin2 Receptor-Mediated Orexigenic Effect: Role of Neuropeptide Y and Opioid Signaling Pathways in Rats. Endocrinology. 151(9). 4224–4235. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact